Citrullination Alters the Antiviral and Immunomodulatory Activities of the Human Cathelicidin LL-37 During Rhinovirus Infection

被引:42
|
作者
Casanova, Victor [1 ]
Sousa, Filipa Henderson [1 ]
Shakamuri, Priyanka [2 ]
Svoboda, Pavel [2 ]
Buch, Chloe [1 ]
D'Acremont, Mathilde [1 ]
Christophorou, Maria A. [3 ]
Pohl, Jan [2 ]
Stevens, Craig [1 ]
Barlow, Peter [1 ]
机构
[1] Edinburgh Napier Univ, Sch Appl Sci, Edinburgh, Midlothian, Scotland
[2] US Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Div Sci Resources, Atlanta, GA USA
[3] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
关键词
rhinovirus; virus; inflammation; peptide; LL-37; cathelicidin; citrullination; PEPTIDYLARGININE DEIMINASE 2; POSTTRANSLATIONAL MODIFICATION; ANTIBACTERIAL PEPTIDES; ANTIMICROBIAL PEPTIDES; HISTONE DEIMINATION; IN-VITRO; SMOKING; ASTHMA; INTERLEUKIN-8; INFLAMMATION;
D O I
10.3389/fimmu.2020.00085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human rhinoviruses (HRV) are the most common cause of viral respiratory tract infections. While normally mild and self-limiting in healthy adults, HRV infections are associated with bronchiolitis in infants, pneumonia in immunocompromised patients, and exacerbations of asthma and COPD. The human cathelicidin LL-37 is a host defense peptide (HDP) with broad immunomodulatory and antimicrobial activities that has direct antiviral effects against HRV. However, LL-37 is known to be susceptible to the enzymatic activity of peptidyl arginine deiminases (PAD), and exposure of the peptide to these enzymes results in the conversion of positively charged arginines to neutral citrullines (citrullination). Here, we demonstrate that citrullination of LL-37 reduced its direct antiviral activity against HRV. Furthermore, while the anti-rhinovirus activity of LL-37 results in dampened epithelial cell inflammatory responses, citrullination of the peptide, and a loss in antiviral activity, ameliorates this effect. This study also demonstrates that HRV infection upregulates PAD2 protein expression, and increases levels of protein citrullination, including histone H3, in human bronchial epithelial cells. Increased PADI gene expression and HDP citrullination during infection may represent a novel viral evasion mechanism, likely applicable to a wide range of pathogens, and should therefore be considered in the design of therapeutic peptide derivatives.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Effect of targeted minimal sequence variations on the structure and biological activities of the human cathelicidin LL-37
    Pacor, Sabrina
    Guida, Filomena
    Xhindoli, Daniela
    Benincasa, Monica
    Gennaro, Renato
    Tossi, Alessandro
    PEPTIDE SCIENCE, 2018, 110 (05):
  • [22] Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model
    Simonetti, Oriana
    Cirioni, Oscar
    Goteri, Gaia
    Lucarini, Guendalina
    Kamysz, Elzbieta
    Kamysz, Wojciech
    Orlando, Fiorenza
    Rizzetto, Giulio
    Molinelli, Elisa
    Morroni, Gianluca
    Ghiselli, Roberto
    Provinciali, Mauro
    Giacometti, Andrea
    Offidani, Annamaria
    ANTIBIOTICS-BASEL, 2021, 10 (10):
  • [23] Carbon Nanoparticles Inhibit the Antimicrobial Activities of the Human Cathelicidin LL-37 through Structural Alteration
    Findlay, Fern
    Pohl, Jan
    Svoboda, Pavel
    Shakamuri, Priyanka
    McLean, Kevin
    Inglis, Neil F.
    Proudfoot, Lorna
    Barlow, Peter G.
    JOURNAL OF IMMUNOLOGY, 2017, 199 (07): : 2483 - 2490
  • [24] Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections
    Ahmed, Aslaa
    Siman-Tov, Gavriella
    Keck, Forrest
    Kortchak, Stephanie
    Bakovic, Allison
    Risner, Kenneth
    Lu, Timothy K.
    Bhalla, Nishank
    de la Fuente-Nunez, Cesar
    Narayanan, Aarthi
    ANTIVIRAL RESEARCH, 2019, 164 : 61 - 69
  • [25] Expression of a human cathelicidin antimicrobial peptide, LL-37, in amniotic fluid with neonatal or maternal infection
    Yoshio, H
    Yamada, M
    Yoshida, M
    Takeuchi, A
    Fujii, S
    Kunii, Y
    Kageyama, M
    Yokoi, Y
    Yamauchi, Y
    Agerberth, B
    PEDIATRIC RESEARCH, 2005, 58 (02) : 427 - 427
  • [26] LL-37, the only human member of the cathelicidin family of antimicrobial peptides
    Durr, Ulrich H. N.
    Sudheendra, U. S.
    Ramamoorthy, Ayyalusamy
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2006, 1758 (09): : 1408 - 1425
  • [27] Pulmonary defense and the human cathelicidin hCAP-18/LL-37
    Fahy, RJ
    Wewers, MA
    IMMUNOLOGIC RESEARCH, 2005, 31 (02) : 75 - 89
  • [28] In silico assessment of missense point mutations on human cathelicidin LL-37
    Porto, William F.
    Alencar, Sergio A.
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2023, 118
  • [29] Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity
    Kilari, Geeta
    Tran, Jacquelyn
    Blyth, Graham A. D.
    Cobo, Eduardo R.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2025, 1867 (03):
  • [30] Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease
    Kusaka, S.
    Nishida, A.
    Takahashi, K.
    Bamba, S.
    Yasui, H.
    Kawahara, M.
    Inatomi, O.
    Sugimoto, M.
    Andoh, A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 191 (01): : 96 - 106